NASDAQ : TWST
Twist Bioscience Corporation — Key statistics
Healthcare · Diagnostics & Research · United States
Last price 152.78 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 9.58B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 9.58B |
| Enterprise Value | 9.52B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 62.71M |
| Shares Outstanding | 62.71M |
| Shares Change (YoY) | +3.44% |
| Shares Change (QoQ) | +1.14% |
| Owned by Insiders (%) | 1.31% |
| Owned by Institutions (%) | 126.57% |
| Float | 61.89M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 22.19 |
| Forward PS | 18.27 |
| PB Ratio | 21.48 |
| P/TBV Ratio | 27.31 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 22.05 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.67 |
| Quick Ratio | 1.98 |
| Debt / Equity | 0.24 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -29.59% |
| Return on Assets (ROA) | -13.09% |
| Return on Invested Capital (ROIC) | -15.30% |
| Return on Capital Employed (ROCE) | -24.95% |
| Weighted Average Cost of Capital (WACC) | 16.12% |
| Revenue Per Employee | $441,060 |
| Profits Per Employee | -$139,650 |
| Employee Count | 979 |
| Asset Turnover | 0.66 |
| Inventory Turnover | 6.79 |
Taxes
| Measure | Value |
|---|
| Income Tax | 864,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.19 |
| 52-Week Price Change | +374.33% |
| 50-Day Moving Average | 153.11 |
| 200-Day Moving Average | 89.02 |
| Relative Strength Index (RSI) | 49.24 |
| Average Volume (20 Days) | 3,043,251 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 10.21M |
| Short Previous Month | 10.57M |
| Short % of Shares Out | 16.28% |
| Short % of Float | 16.49% |
| Short Ratio (days to cover) | 3.22 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 431.80M |
| Gross Profit | 224.39M |
| Operating Income | -137.77M |
| Pretax Income | -135.85M |
| Net Income | -136.72M |
| EBITDA | -115.28M |
| EBIT | -137.77M |
| Loss Per Share | -$2.23 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 166.84M |
| Total Debt | 108.59M |
| Net Cash | 58.25M |
| Net Cash Per Share | $0.93 |
| Equity (Book Value) | 445.74M |
| Book Value Per Share | 7.11 |
| Working Capital | 201.04M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -53.07M |
| Capital Expenditures | -40.05M |
| Depreciation & Amortization | 22.49M |
| Net Borrowing | n/a |
| Free Cash Flow | -93.12M |
| FCF Per Share | -$1.49 |
Margins
| Measure | Value |
|---|
| Gross Margin | 51.97% |
| Operating Margin | -31.91% |
| Pretax Margin | -31.46% |
| Profit Margin | -31.66% |
| EBITDA Margin | -26.70% |
| EBIT Margin | -31.91% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -3.44% |
| Shareholder Yield | -3.44% |
| Earnings Yield | -1.46% |
| FCF Yield | -0.97% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $168.25 |
| Price Target Difference | 10.13% |
| Analyst Consensus | Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (3Y) | 19.70% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 4.26 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |